Trust Co of Kansas Invests $258,000 in Becton, Dickinson and Company (NYSE:BDX)

Trust Co of Kansas acquired a new position in Becton, Dickinson and Company (NYSE:BDX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,070 shares of the medical instruments supplier’s stock, valued at approximately $258,000.

A number of other hedge funds have also recently made changes to their positions in BDX. Jennison Associates LLC raised its holdings in Becton, Dickinson and Company by 4.9% during the 1st quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock valued at $99,562,000 after buying an additional 18,786 shares during the last quarter. Norden Group LLC increased its position in Becton, Dickinson and Company by 2,086.7% during the 1st quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock valued at $12,853,000 after purchasing an additional 49,559 shares during the period. Franklin Street Advisors Inc. NC purchased a new position in Becton, Dickinson and Company during the 1st quarter valued at $11,998,000. Avity Investment Management Inc. increased its position in Becton, Dickinson and Company by 3.5% during the 1st quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier’s stock valued at $40,257,000 after purchasing an additional 5,527 shares during the period. Finally, Caden Capital Partners LP increased its position in Becton, Dickinson and Company by 26.7% during the 4th quarter. Caden Capital Partners LP now owns 83,417 shares of the medical instruments supplier’s stock valued at $20,340,000 after purchasing an additional 17,599 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Down 0.1 %

NYSE:BDX opened at $237.17 on Wednesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The company has a market capitalization of $68.54 billion, a PE ratio of 52.24, a P/E/G ratio of 1.92 and a beta of 0.42. The firm’s 50-day moving average price is $236.65 and its 200-day moving average price is $235.51. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $269.52.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.31 by $0.19. The business had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.96 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 13.1 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, September 30th. Shareholders of record on Monday, September 9th were paid a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 1.60%. The ex-dividend date was Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Raymond James reduced their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Evercore ISI boosted their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, Stifel Nicolaus upped their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.